This study describes a novel method which could be developed into a test system of evaluating the efficacy of antileprosy drugs. The method estimates incorporation of [14C]acetate into lipids of Mycobacterium leprae maintained within the 33B Schwannoma cell line. Schwannoma cell-resident M. leprae cells incorporated significant levels of radiolabel within their lipids during 12 days of incubation in vitro. This incorporation was markedly reduced by 5 ,g of rifampin per ml (decrease, 81.62%); this decrease was observed within 24 h of addition of the drug. Dapsone also reduced the radiolabel incorporation into the lipids, but to a lesser extent (decrease, 27.58%). This system was also able to differentiate between rifampin-sensitive and -resistant strains of mycobacteria. It is suggested that since the effect of bacteriostatic (dapsone) and bactericidal (rifampin) drugs could be detected by using this technique, it may prove useful in screening novel drugs acting against M. leprae.
The development of new drugs against Mycobacterium leprae is still a very important field in leprosy research. One of the earliest described and most widely used methods for estimating drug efficacy is the mouse footpad test (21) . The main disadvantage of this system, however, is the long time (9 to 12 months) required for evaluating each drug. To overcome this difficulty, various in vitro methods were described. Because M. leprae cannot be directly cultivated in vitro, the assays had to depend on the indirect estimation of other biological activities, such as the estimation of bacillary ATP (3) and the enzyme esterase by FDA staining (11, 18) . However, there is speculation about the quantitative correlation of viability in these two assays (7) . Also, dapsone, the most commonly used antileprosy drug, induced no decrease in ATP levels in vitro (5) . Other tests for drug screening are based on the principle of inhibition of incorporation of radiolabeled precursors into active bacillary metabolites. Some of the precursors used were [3H]thymidine (13, 20) , [3H]3,4-dihydroxyphenylalanine (1) , and [3H]hypoxanthine (9) . On the whole, the incorporation of these precursors in bacilli maintained in synthetic media or within macrophages was poor and not consistent. To overcome these problems, we estimated the incorporation of
[14C]acetate into M. leprae lipids. Earlier, we reported that radiolabeled acetate is incorporated into PGL-1 of bacilli maintained within Schwannoma cells (15) . Our results demonstrated that uptake of this radiolabel into PGL-1 correlated well with the viability of the pathogen and was inhibited in the presence of antileprosy drugs (12) . Incorporation of [14C]palmitic acid into PGL-1 of M. leprae within macrophages has also been demonstrated to be a measure of its viability (19) . Even though this serves as a good drug testing assay, in order to simplify the test for routine use, we modified the assay by estimating [14C]acetate incorporation into total bacillary lipids, as the pattern of incorporation into this fraction remained similar to that observed for PGL-1.
The suitability of this drug screening model was affirmed by first studying the kinetics of action of the antileprosy drug rifampin (RFP) and by examining the efficacy of this system to differentiate between drug-sensitive and -resistant strains.
MATERIALS AND METHODS
Chemicals. The culture medium, Dulbecco's minimum essential medium, and fetal calf serum were purchased from GIBCO Laboratories, Grand Island, N.Y. RFP was purchased from Sigma Chemical Co., St. Louis, Mo., and 4,4'-diaminodiphenyl sulfone (DDS or dapsone) was purchased from Burroughs Wellcome Co., Bombay, India. All solvents used for lipid extraction were of analytical grade and were obtained from Glaxo Laboratories, Bombay, India.
Isolation of bacilli. M. leprae were freshly isolated from infected armadillo tissue by the method of Ambrose et al. (1) . FMR isolates of M. leprae, which are acid-fast bacilli isolated from human lepromas, were incubated in spent medium from cultures of mouse dorsal root ganglia supplemented with 10% human type AB serum. These isolates later adapt to growth in Dubos medium and were routinely maintained by repeated passage. Various characteristics of these organisms were studied, including their response to antileprosy drugs. Some of these strains were resistant to RFP and showed no inhibition of growth in the presence of this drug (10 Bacillary isolation from 33B cells. 33B cells were harvested with 0.25% (wt/vol) trypsin and washed twice with phosphate-buffered saline. Bacilli were released by sonication at 23 kHz in a Soniprep 150 ultrasonic disintegrator for 2 min. The host cellular debris was removed by centrifugation at 220 x g for 10 min, and the bacillary pellet was recovered by ultracentrifugation at 10,000 x g for 45 min. The bacillary pellet was washed two times with phosphate-buffered saline, and the bacilli recovered were counted as per the method described by Hart and Rees (6) . To check for any contaminating organisms, the bacilli were inoculated onto nutrient agar and Lowenstein Jensen media.
Lipid extraction. Lipids were extracted from the bacillary pellet by the method of Bligh and Dyer (2). This total lipid fraction was dried under vacuum and dissolved in a small volume of chloroform. The incorporated radioactivity was estimated by counting on a Kontron 300 scintillation counter. Counts were expressed as disintegrations per minute for 106 bacilli after subtraction of any counts obtained for control uninfected cultures.
Addition of drugs. RFP was added to the respective cultures together with the radiolabel at concentrations of 1, 5, and 10 ,ug/ml. The drug was replenished each time by addition of fresh medium. Further experiments were conducted with 5 ,ug of RFP per ml, as this concentration was optimal. We also used 5 ,ug of DDS per ml to study the effect of this drug on [14C]acetate incorporation into M. leprae lipids.
The effect of RFP on the [14C]acetate uptake into 33B cells alone was also estimated by using the same concentration (5 ,ug/ml) of the drug, and this effect was compared with those for cell cultures maintained in the absence of the drug. tion of radiolabel incorporation is due to decrease of the viability of Schwannoma cell-resident M. leprae, as prior formalin fixation of these bacilli also resulted in a low level of incorporation of the radiolabel (P < 0.005).
The subsequent experiments where bacilli were exposed to RFP for different time periods, i.e., 1 day, 3 days, and 12 days, revealed that the presence of drug for the initial 24 h after phagocytosis was sufficient to kill the microorganisms and reduce the incorporation to minimal levels (Table 4) . Longer periods of RFP treatment caused no further reduction in the uptake of the radiolabel.
The next series of experiments were designed to find out whether this system could be used to detect emergence of drug-resistant organisms. For this, FMR isolates with known characteristics for RFP resistance and sensitivity were used. RFP decreased incorporation of [14C]acetate into total lipids of FMR 51 isolate, a RFP-sensitive strain, whereas it had no effect on radiolabel incorporation into FMR 279R, known to be RFP resistant (Table 5) . (16, 17, 19) . Further, in this system the radiolabel incorporation is higher than in bacilli maintained directly in media (1, 8, 9) . The 33B cell line was used as the host for in vitro study of M. leprae as it is closer to the natural host of the bacilli, Schwann cells, in which limited multiplication of these bacilli has been observed (14) .
Since both of the antileprosy agents RFP and DDS, which have different modes of action, inhibit [14C]acetate incorporation into M. leprae lipids, it is likely that this incorporation is inhibited as an indirect effect, possibly following overall impaired metabolic competence of the bacilli. This would then be a good method of screening novel agents with different primary effects. 
